Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: VTI IJH VB VBK VXF MDY IBB XBI FBT IWP

Index	-	P/E	26.59	EPS (ttm)	4.67	Insider Own	2.67%	Shs Outstand	100.10M	Perf Week	-12.10%
Market Cap	12.46B	Forward P/E	16.49	EPS next Y	7.53	Insider Trans	-3.64%	Shs Float	97.69M	Perf Month	-8.28%
Enterprise Value	11.45B	PEG	0.60	EPS next Q	1.09	Inst Own	98.90%	Short Float	3.42%	Perf Quarter	-15.48%
Income	478.60M	P/S	4.35	EPS this Y	27.16%	Inst Trans	1.70%	Short Ratio	3.09	Perf Half Y	-5.48%
Sales	2.86B	P/B	3.82	EPS next Y	26.73%	ROA	11.13%	Short Interest	3.34M	Perf YTD	-12.49%
Book/sh	32.50	P/C	8.41	EPS next 5Y	27.58%	ROE	16.38%	52W High	160.18 -22.51%	Perf Year	6.20%
Cash/sh	14.75	P/FCF	16.64	EPS past 3/5Y	44.05% 2.31%	ROIC	13.05%	52W Low	84.23 47.36%	Perf 3Y	19.90%
Dividend Est.	-	EV/EBITDA	17.17	Sales past 3/5Y	24.32% 22.29%	Gross Margin	98.18%	Volatility	4.38% 3.12%	Perf 5Y	8.78%
Dividend TTM	-	EV/Sales	4.00	EPS Y/Y TTM	41.73%	Oper. Margin	22.25%	ATR (14)	4.60	Perf 10Y	244.40%
Dividend Ex-Date	-	Quick Ratio	3.30	Sales Y/Y TTM	21.45%	Profit Margin	16.73%	RSI (14)	30.92	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	47.94%	SMA20	-8.35%	Beta	0.34	Target Price	177.29
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	28.33%	SMA50	-11.94%	Rel Volume	1.96	Prev Close	123.10
Employees	2000	LT Debt/Eq	0.13	Earnings	Feb 11 AMC	SMA200	-8.49%	Avg Volume	1.08M	Price	124.12
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.97% 1.90%	Trades		Volume	2,122,668	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130

Show Previous Ratings

Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Loading…
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
12:10PM	Loading…
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
04:05PM	Loading…
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM

Open in Screener

GMED

Globus Medical Inc

Feb 13 • 04:00PM ET

88.09

+0.87 1.00 %

Healthcare • Medical Devices • USA • NYSE

GMED Globus Medical Inc daily Stock Chart

Peers: JNJ SYK BSX ZBH BAX MEDP HOLX IART MTD TFX

| Held by: IJH VTI VB VBK VXF MDY XMHQ IJK SPMD SCHA

Index	-	P/E	28.47	EPS (ttm)	3.09	Insider Own	17.27%	Shs Outstand	112.18M	Perf Week	0.32%
Market Cap	11.86B	Forward P/E	21.15	EPS next Y	4.17	Insider Trans	-0.45%	Shs Float	111.36M	Perf Month	-4.73%
Enterprise Value	11.59B	PEG	1.57	EPS next Q	1.13	Inst Own	84.04%	Short Float	3.70%	Perf Quarter	3.99%
Income	423.78M	P/S	4.28	EPS this Y	22.72%	Inst Trans	3.87%	Short Ratio	2.77	Perf Half Y	46.77%
Sales	2.77B	P/B	2.70	EPS next Y	8.11%	ROA	8.32%	Short Interest	4.12M	Perf YTD	0.89%
Book/sh	32.68	P/C	30.36	EPS next 5Y	13.47%	ROE	10.01%	52W High	101.40 -13.12%	Perf Year	4.71%
Cash/sh	2.90	P/FCF	20.46	EPS past 3/5Y	-19.65% -13.26%	ROIC	9.41%	52W Low	51.79 70.09%	Perf 3Y	48.22%
Dividend Est.	-	EV/EBITDA	15.98	Sales past 3/5Y	38.03% 26.25%	Gross Margin	61.05%	Volatility	2.95% 2.67%	Perf 5Y	30.04%
Dividend TTM	-	EV/Sales	4.18	EPS Y/Y TTM	364.73%	Oper. Margin	16.20%	ATR (14)	2.60	Perf 10Y	289.61%
Dividend Ex-Date	-	Quick Ratio	2.47	Sales Y/Y TTM	11.75%	Profit Margin	15.30%	RSI (14)	45.24	Recom	1.82
Dividend Gr. 3/5Y	- -	Current Ratio	4.13	EPS Q/Q	134.07%	SMA20	-2.38%	Beta	1.07	Target Price	107.00
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	22.91%	SMA50	-1.73%	Rel Volume	0.56	Prev Close	87.22
Employees	5300	LT Debt/Eq	0.02	Earnings	Feb 24 AMC	SMA200	27.33%	Avg Volume	1.49M	Price	88.09
IPO	Aug 03, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	51.13% 4.68%	Trades		Volume	836,773	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	Needham	Hold → Buy	$112
Jan-27-26	Initiated	TD Cowen	Buy	$110
Nov-07-25	Upgrade	Truist	Hold → Buy	$93
Nov-07-25	Upgrade	BofA Securities	Neutral → Buy	$91
Oct-28-25	Resumed	Stifel	Hold	$64
May-27-25	Downgrade	BTIG Research	Buy → Neutral
Jan-10-25	Upgrade	BofA Securities	Underperform → Neutral	$97
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$83 → $100
Aug-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$60 → $78
May-20-24	Upgrade	Piper Sandler	Neutral → Overweight	$60 → $80
Mar-18-24	Upgrade	BTIG Research	Neutral → Buy	$60
Oct-20-23	Initiated	ROTH MKM	Buy	$75
Sep-19-23	Upgrade	Stifel	Hold → Buy	$61
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$67
Feb-13-23	Downgrade	BofA Securities	Buy → Underperform	$83 → $63
Feb-10-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$67
Feb-10-23	Downgrade	Truist	Buy → Hold	$85 → $70
Feb-10-23	Downgrade	Needham	Buy → Hold
Feb-10-23	Downgrade	Loop Capital	Buy → Hold	$90 → $70
Feb-10-23	Downgrade	BTIG Research	Buy → Neutral

Show Previous Ratings

Today 08:54AM	Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings (Zacks)
Feb-15-26 06:53AM	Globus Medical Inc. (GMED) Gains Positive Attention Amid Improving Outlook (Insider Monkey)
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
Feb-12-26 04:30PM	Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call (GlobeNewswire)
10:00AM	Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
09:45AM	Loading…
Feb-11-26 09:45AM	Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term (Zacks)
Feb-10-26 08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 08:02AM	Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance (Zacks)
Feb-05-26 10:45AM	Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings? (Zacks)
09:40AM	Here's Why Globus Medical (GMED) is a Strong Value Stock (Zacks)
08:09AM	ALGN Stock Climbs on Q4 Earnings and Revenue Beat, Margins Down (Zacks)
Feb-04-26 11:03PM	2 Reasons to Watch GMED and 1 to Stay Cautious (StockStory)
Feb-03-26 11:40AM	GMED vs. PEN: Which Stock Is the Better Value Option? (Zacks)
10:23AM	DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand (Zacks)
Feb-02-26 04:06PM	Nvidia, Google Lead Slew Of Stocks To Watch With This Caveat (Investor's Business Daily)
09:50AM	Loading…
Jan-27-26 09:50AM	Here's Why Globus Medical (GMED) is a Strong Momentum Stock (Zacks)
07:45AM	Here's What Lifted Globus Medical (GMED) in Q4 (Insider Monkey)
Jan-26-26 12:23PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
09:50AM	China Remains Competitive: Can ISRG Defend Share Amid Local Rivals? (Zacks)
09:45AM	Here's Why Globus Medical (GMED) is a Strong Growth Stock (Zacks)
Jan-21-26 11:37PM	1 Mooning Stock to Keep an Eye On and 2 Facing Challenges (StockStory)
12:10PM	Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-20-26 08:36AM	Should You Still Hold GMED Stock in Your Portfolio? (Zacks)
Jan-16-26 11:46AM	Globus Medical Stock Operating In A Buy Zone After Strong Preliminary Results (Investor's Business Daily)
Jan-12-26 11:32PM	2 Healthcare Stocks to Keep an Eye On and 1 We Ignore (StockStory)
Jan-11-26 11:37PM	3 Profitable Stocks Worth Your Attention (StockStory)
Jan-09-26 09:45AM	Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term (Zacks)
Jan-08-26 04:39PM	Stocks Settle Mixed on Sector Rotation (Barchart)
11:43AM	Globus Medical jumps 9% after upbeat revenue and earnings outlook (GuruFocus.com)
11:23AM	Stock Indexes Mixed on Big Tech Weakness and Higher Bond Yields (Barchart)
09:50AM	Loading…
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:31AM	Defense stocks rebound, and other early market movers (MarketWatch)
05:12AM	Stock Market Today: Dow, S&P 500 and Nasdaq point to lower open; Nvidia in focus on China chip sales hope; precious metals retreat (MarketWatch)
Jan-07-26 07:11PM	Why Globus Medical Stock Is Flying Higher in After-Hours Trading (Motley Fool)
04:27PM	Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results (GlobeNewswire)
Jan-03-26 08:00AM	Google, Other AI Stocks Trade Near Buy Points. One Named 'Top Stock' For 2026 (Investor's Business Daily)
Dec-31-25 07:32AM	ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery? (Zacks)
Dec-23-25 09:45AM	Here's Why Globus Medical (GMED) is a Strong Growth Stock (Zacks)
Dec-22-25 03:00PM	Globus Medical (GMED) Stock Trades Up, Here Is Why (StockStory)
Dec-19-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-18-25 11:12PM	Dow Jones Futures: Stocks Rise On Micron, Inflation, But Don't Do This; Nike, Fed Earnings Late (Investor's Business Daily)
03:11PM	Globus Medical (GMED) Stock Trades Up, Here Is Why (StockStory)
09:08AM	3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026 (Zacks)
Dec-08-25 10:33PM	Medical Devices & Supplies - Specialty Stocks Q3 Recap: Benchmarking Globus Medical (NYSE:GMED) (StockStory)
Dec-04-25 11:43AM	IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge? (Zacks)
09:45AM	Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term (Zacks)
08:27AM	Should You Hold STERIS Stock in Your Portfolio for Now? (Zacks)
Dec-03-25 12:45PM	Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
12:43PM	TMO Stock Benefits From New Bioprocess Design Center in Asia (Zacks)
11:40AM	GMED or PEN: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
08:14AM	Should You Continue to Hold RMD Stock in Your Portfolio? (Zacks)
08:08AM	The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock (Zacks)
Dec-02-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
08:25AM	HSIC Stock Benefits From Expanded Partnership With vVARDIS (Zacks)
07:53AM	Should You Continue to Hold LH Stock in Your Portfolio? (Zacks)
Dec-01-25 05:12PM	Stocks To Watch As Google Drives Rattled But Rebounding Market (Investor's Business Daily)
09:04AM	5 Momentum Stocks to Buy for December After a Mixed November (Zacks)
07:52AM	HSIC Stock Set to Benefit From Henry Schein One's Workflow Launch (Zacks)
Nov-26-25 03:27AM	Zacks.com featured highlights include Take-Two Interactive, Globus, Rockwell Automation, Canadian and VICI (Zacks)
Nov-25-25 02:42PM	Relative Strength Soars On Medtronic Stock. Here's How To Get Bullish (Investor's Business Daily)
08:24AM	Retail Sales, PPI, ADP Jobs Data May Shape Fed Outlook (Live Coverage) (Investor's Business Daily)
07:03AM	5 Stocks With Strong Sales Growth to Bet on Amid Volatile Markets (Zacks)
Nov-24-25 05:15PM	Stock Market Roars To Key Level As Tesla, Palantir, Broadcom Jump; What To Do Now (Investor's Business Daily)
01:47PM	This Medical Products Stock Hits Buy Point As Health Care Names Rally (Investor's Business Daily)
11:35AM	Stock Market Today: Dow, Nasdaq Up As This Stock Tests Entry; Health Plays Pop (Live Coverage) (Investor's Business Daily)
09:55AM	Should You Buy Globus Medical (GMED) After Golden Cross? (Zacks)
Nov-20-25 05:46PM	2 Unpopular Stocks That Should Get More Attention and 1 We Ignore (StockStory)
09:16AM	DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal (Zacks)
Nov-19-25 01:45PM	Medtronic Stock Sees RS Rating Pumps Higher (Investor's Business Daily)
Nov-18-25 01:56PM	10 Years Later: 5 Lesser-Known Rule Breakers (Motley Fool)
Nov-17-25 09:33AM	5 Top Stocks Driven by Strong Relative Price Strength Now (Zacks)
Nov-14-25 12:45PM	Globus Medical (GMED) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
10:19AM	Medical Products Leader In Base After 36% Stock Surge On Blowout Quarterly Earnings (Investor's Business Daily)
09:50AM	Here's Why Globus Medical (GMED) is a Strong Momentum Stock (Zacks)
08:21AM	Varied Growth Drivers Led Antipodes Global Value Strategy to Add Globus Medical (GMED) to Its Portfolio (Insider Monkey)
Nov-13-25 08:52AM	Is Force Feedback the Next Big Catalyst for ISRG's da Vinci Sales? (Zacks)
12:35AM	5 Revealing Analyst Questions From Globus Medical's Q3 Earnings Call (StockStory)
Nov-11-25 09:45AM	Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Nov-10-25 11:41PM	2 Momentum Stocks with Exciting Potential and 1 We Find Risky (StockStory)
Nov-09-25 12:40PM	Globus Medical (GMED) Soars 38.9% on Stellar Q3 (Insider Monkey)
Nov-07-25 04:21PM	These Stocks Moved the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More (Barrons.com) +35.94%
04:14PM	Here's What Stimulated Global Medical's Third-Quarter Blowout (Investor's Business Daily)
02:17PM	These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More (Barrons.com)
01:11PM	Why Globus Medical (GMED) Stock Is Trading Up Today (StockStory)
11:08AM	Globus Medical Stock Soars After Earnings. Where It's Seeing the Strength. (Barrons.com)
11:04AM	Todays Market Moving Stocks: Affirm Holdings, Expedia, and Globus Medical (24/7 Wall St.)
09:26AM	GMED Q3 Deep Dive: U.S. Spine Momentum and Nevro Integration Drive Upbeat Results (StockStory)
06:36AM	Stock Market Today: U.S. Stock Futures Tumble After Overnight Reprieve, Extending Week-Long Tech Struggle (TheStreet)
Nov-06-25 07:30PM	Globus Medical (GMED) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:55PM	Globus Medical (GMED) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:55PM	Globus Medical: Q3 Earnings Snapshot (Associated Press Finance)
05:08PM	Globus Medical's (NYSE:GMED) Q3: Strong Sales, Stock Jumps 19.2% (StockStory)
04:15PM	Globus Medical Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-05-25 07:10PM	CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
11:54AM	Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock? (Zacks)
09:15AM	Globus Medical (GMED) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Nov-04-25 10:12PM	Globus Medical (GMED) Q3 Earnings: What To Expect (StockStory)
06:20PM	NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:39AM	Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock? (Zacks)

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huller Kelly	Officer	Feb 12 '26	Proposed Sale	87.60	10,000	876,000		Feb 12 12:12 PM
Kline Kyle	Senior Vice President, CFO	Jan 08 '26	Option Exercise	51.87	3,594	186,421	3,594	Jan 12 05:40 PM
Kline Kyle	Senior Vice President, CFO	Jan 08 '26	Sale	101.10	3,594	363,353	0	Jan 12 05:40 PM
Norwalk Leslie V	Director	Jan 08 '26	Sale	101.10	2,000	202,200	10,419	Jan 12 05:36 PM
Kline Kyle	Officer	Jan 08 '26	Proposed Sale	101.05	3,594	363,167		Jan 08 01:52 PM
Norwalk Leslie V	Director	Jan 08 '26	Proposed Sale	101.00	2,000	202,000		Jan 08 01:10 PM
Norwalk Leslie V	Director	Dec 12 '25	Sale	88.85	4,000	355,400	12,419	Dec 16 04:18 PM
Norwalk Leslie V	Director	Dec 12 '25	Proposed Sale	88.75	4,000	355,000		Dec 12 04:00 PM
Paul David C	Executive Chairman	Dec 08 '25	Option Exercise	25.52	34,375	877,250	60,417	Dec 10 04:37 PM
Kline Kyle	Senior Vice President, CFO	Dec 01 '25	Option Exercise	59.86	18,542	1,109,876	18,542	Dec 03 08:23 PM
Kline Kyle	Senior Vice President, CFO	Dec 01 '25	Sale	90.00	18,542	1,668,780	0	Dec 03 08:23 PM
Kline Kyle	Officer	Dec 01 '25	Proposed Sale	89.95	18,542	1,667,847		Dec 01 03:59 PM
Huller Kelly	SVP, GC, Corporate Secretary	Nov 25 '25	Option Exercise	25.96	7,500	194,700	7,500	Nov 28 05:31 PM
Huller Kelly	SVP, GC, Corporate Secretary	Nov 25 '25	Sale	90.00	7,500	675,000	0	Nov 28 05:31 PM
Huller Kelly	Officer	Nov 25 '25	Proposed Sale	90.00	7,500	675,000		Nov 25 11:07 AM
Davidar David D	Director	Nov 12 '25	Option Exercise	25.52	25,000	638,000	541,275	Nov 13 05:12 PM
Davidar David D	Director	Nov 12 '25	Sale	86.00	25,000	2,150,005	516,275	Nov 13 05:12 PM
ZARRILLI STEPHEN T	Director	Nov 11 '25	Option Exercise	44.14	25,000	1,103,500	25,000	Nov 13 05:06 PM
ZARRILLI STEPHEN T	Director	Nov 11 '25	Sale	84.29	25,000	2,107,258	0	Nov 13 05:06 PM
Davidar David D	Director	Nov 12 '25	Proposed Sale	85.95	25,000	2,148,750		Nov 12 12:35 PM
ZARRILLI STEPHEN T	Director	Nov 11 '25	Proposed Sale	84.24	25,000	2,106,000		Nov 12 08:45 AM
RHOADS ANN D	Director	Nov 10 '25	Proposed Sale	85.00	2,000	170,000		Nov 10 04:55 PM
RHOADS ANN D	Director	Nov 07 '25	Sale	81.00	8,000	648,000	17,384	Nov 10 04:15 PM
RHOADS ANN D	Director	Nov 10 '25	Sale	85.00	2,000	170,000	15,384	Nov 10 04:15 PM
RHOADS ANN D	Director	Nov 07 '25	Proposed Sale	80.96	8,000	647,681		Nov 07 12:17 PM
RHOADS ANN D	Director	Sep 15 '25	Sale	58.46	10,000	584,600	25,384	Sep 16 05:16 PM
RHOADS ANN D	Director	Sep 15 '25	Proposed Sale	58.40	10,000	584,000		Sep 15 03:51 PM
RHOADS ANN D	Director	Feb 28 '25	Sale	78.68	7,500	590,100	35,384	Mar 04 04:38 PM
RHOADS ANN D	Director	Feb 28 '25	Proposed Sale	78.67	7,500	590,000		Feb 28 11:05 AM

NBIX

Neurocrine Biosciences, Inc

GMED

Globus Medical Inc

Upgrade your FINVIZ experience